Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 514-520

  Qin, You ^a   Sun, Chun Yan ^a   Lu, Fu Rong ^a   Shu, Xiang Rong ^a   Yang, Di ^a   Chen, Lei ^a   She, Xiao Mei ^a   Gregg, Nicholas Miller ^b   Guo, Tao ^a   Hu, Yu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cardamonin; Multiple myeloma; Natural products; Nuclear factor B; Traditional Chinese medicine

Indexed keywords

CARDAMONIN; CASPASE 3; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; I KAPPA B ALPHA; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; COX 2 GENE; DOWN REGULATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; GENE EXPRESSION; GENE PRODUCT; HUMAN; HUMAN CELL; ICAM 1 GENE; IN VITRO STUDY; INHIBITION KINETICS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VEGF GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHALCONES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84857236804     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.014     Document Type: Article

References (35)

1. Paterson I., Anderson E.A. Chemistry. The renaissance of natural products as drug candidates. Science 2005, 310:451-453.
2. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70:461-477.
3. Lu F.R., Shen L., Qin Y., Gao L., Li H., Dai Y. Clinical observation on Trigonella foenum graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin J Integr Med 2008, 14:56-60.
4. Efferth T., Li P.C., Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007, 13:353-361.
5. Qin Y., Shen L., Lu F.R., Shi W., Liu J.G. Effect of Xiaoyu Zhixue Tablet on the expression of platelet membrane glycoprotein I b/IX/V complex in patients with chronic renal failure. Chin J Integr Med 2008, 14:83-87.
6. Wang S., Zhou L., He W., Hu Z. Separation and determination of alpinetin and cardamonin by reverse micelle electrokinetic capillary chromatography. J Pharm Biomed Anal 2007, 43:1557-1561.
7. Jantan I., Raweh S.M., Sirat H.M., Jamil S., Mohd Yasin Y.H., Jalil J., et al. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. Phytomedicine 2008, 15:306-309.
8. Tang J., Li N., Dai H., Wang K. Chemical constituents from seeds of Aplinia katsumadai, inhibition on NF-kappaB activation and anti-tumor effect. Zhongguo Zhong Yao Za Zhi 2010, 35:1710-1714.
9. Wang Z.T., Lau C.W., Chan F.L., Yao X., Chen Z.Y., He Z.D., et al. Vasorelaxant effects of cardamonin and alpinetin from Alpinia henryi K Schum. J Cardiovasc Pharmacol 2001, 37:596-606.
10. Ahmad S., Israf D.A., Lajis N.H., Shaari K., Mohamed H., Wahab A.A., et al. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. Eur J Pharmacol 2006, 538:188-194.
11. Hatziieremia S., Gray A.I., Ferro V.A., Paul A., Plevin R. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages. Br J Pharmacol 2006, 149:188-198.
12. Israf D.A., Khaizurin T.A., Syahida A., Lajis N.H., Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol Immunol 2007, 44:673-679.
13. Lee J.H., Jung H.S., Giang P.M., Jin X., Lee S., Son P.T., et al. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J Pharmacol Exp Ther 2006, 316:271-278.
14. Dalton W.S. Drug resistance and drug development in multiple myeloma. Semin Oncol 2002, 29:21-25.
15. Bommert K., Bargou R.C., Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006, 42:1574-1580.
16. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
17. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184.
18. Li Z.W., Chen H., Campbell R.A., Bonavida B., Berenson J.R. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008, 15:391-399.
19. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.
20. Mei H., Shi W., Pang Z., Wang H., Lu W., Jiang X., et al. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 2010, 31:5619-5626.
21. Salic A., Mitchison T.J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008, 105:2415-2420.
22. Sun C.Y., Hu Y., Guo T., Wang H.F., Zhang X.P., He W.J., et al. Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol Sin 2006, 27:1447-1452.
23. Baskic D., Popovic S., Ristic P., Arsenijevic N.N. Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int 2006, 30:924-932.
24. Hu Y., Sun C.Y., Huang J., Hong L., Zhang L., Chu Z.B. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl) 2007, 120:1672-1677.
25. Sun C., Hu Y., Liu X., Wu T., Wang Y., He W., et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 2006, 165:9-19.
26. Fernandes-Alnemri T., Litwack G., Alnemri E.S. CPP32 a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994, 269:30761-30764.
27. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
28. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252.
29. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990, 4:2860-2867.
30. Bhardwaj A., Sethi G., Vadhan-Raj S., Bueso-Ramos C., Takada Y., Gaur U., et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109:2293-2302.
31. Luqman S., Pezzuto J.M. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 2010, 24:949-963.
32. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
33. Shimizu H., Mitomo K., Watanabe T., Okamoto S., Yamamoto K. Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 1990, 10:561-568.
34. Shishodia S., Aggarwal B.B. Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 2002, 35:28-40.
35. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997, 91:243-252.